Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075

Ching Ping Chen, Chih Bo Hu, Kai Chia Yeh, Jen Shin Song, Teng Kuang Yeh, Fei Feng Tung, Ling Ling Hwang, Huan Yi Tseng, Yu Chen Huang, Horng Shing Shy, Su Huei Hsieh, Chien Chang Shen, Hsin Sheng Wang, Hsing Pang Hsieh, Jing Ping Liou, Yu Sheng Chao, Chiung Tong Chen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Antimitotic tubulin-binding BPR0L075 is structurally analogous to the vascular-disrupting combretastatin A-4. Materials and Methods: In vitrei in vivo models of endothelial cells cultures, Matrigel™ plug assay, tumor-bearing nude mice, and murine leukemia cells-inoculated mice were utilized to evaluate BPR0L075 for antiangiogenic and antitumoral activity spectra. Results: BPR0L075 concentration-dependently inhibited proliferation and migration of human umbilical vein endothelial cells (HUVECs), disrupted capillary tube formations of HUVECs and rat aorta endothelial cells, and suppressed in vivo VEGF-mediated angiogenesis in Matrigel™ plugs in mice. Besides inhibiting the colony growth of cancer cells, BPR0L075 suppressed growth of subcutaneously-xenografted human lung, colorectal, and cervical solid tumors in nude mice. Combination treatments of BPR0L075 plus cisplatin, compared to either agent alone, demonstrated a stronger growth inhibition against the tumor xenografts in nude mice and longer lifespan in the leukemia mice. Conclusion: BPR0L075 is an antitumoral and antiangiogenic agent and potentiates the anticancer activity of cisplatin.

Original languageEnglish
Pages (from-to)2813-2822
Number of pages10
JournalAnticancer Research
Volume30
Issue number7
Publication statusPublished - Jul 2010

Fingerprint

Cisplatin
Nude Mice
Human Umbilical Vein Endothelial Cells
Neoplasms
Leukemia
Endothelial Cells
Growth
Antimitotic Agents
Angiogenesis Inhibitors
Tubulin
Heterografts
Vascular Endothelial Growth Factor A
Blood Vessels
Aorta
6-methoxy-3-(3',4',5'-trimethoxybenzoyl)-1H-indole
Cell Culture Techniques
Lung
matrigel

Keywords

  • Angiogenesis
  • Cisplatin
  • Combretastatin
  • Microtubule
  • Vascular disrupting agent

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chen, C. P., Hu, C. B., Yeh, K. C., Song, J. S., Yeh, T. K., Tung, F. F., ... Chen, C. T. (2010). Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. Anticancer Research, 30(7), 2813-2822.

Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. / Chen, Ching Ping; Hu, Chih Bo; Yeh, Kai Chia; Song, Jen Shin; Yeh, Teng Kuang; Tung, Fei Feng; Hwang, Ling Ling; Tseng, Huan Yi; Huang, Yu Chen; Shy, Horng Shing; Hsieh, Su Huei; Shen, Chien Chang; Wang, Hsin Sheng; Hsieh, Hsing Pang; Liou, Jing Ping; Chao, Yu Sheng; Chen, Chiung Tong.

In: Anticancer Research, Vol. 30, No. 7, 07.2010, p. 2813-2822.

Research output: Contribution to journalArticle

Chen, CP, Hu, CB, Yeh, KC, Song, JS, Yeh, TK, Tung, FF, Hwang, LL, Tseng, HY, Huang, YC, Shy, HS, Hsieh, SH, Shen, CC, Wang, HS, Hsieh, HP, Liou, JP, Chao, YS & Chen, CT 2010, 'Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075', Anticancer Research, vol. 30, no. 7, pp. 2813-2822.
Chen CP, Hu CB, Yeh KC, Song JS, Yeh TK, Tung FF et al. Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. Anticancer Research. 2010 Jul;30(7):2813-2822.
Chen, Ching Ping ; Hu, Chih Bo ; Yeh, Kai Chia ; Song, Jen Shin ; Yeh, Teng Kuang ; Tung, Fei Feng ; Hwang, Ling Ling ; Tseng, Huan Yi ; Huang, Yu Chen ; Shy, Horng Shing ; Hsieh, Su Huei ; Shen, Chien Chang ; Wang, Hsin Sheng ; Hsieh, Hsing Pang ; Liou, Jing Ping ; Chao, Yu Sheng ; Chen, Chiung Tong. / Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. In: Anticancer Research. 2010 ; Vol. 30, No. 7. pp. 2813-2822.
@article{233c801f1e424a6390be70e69554ee49,
title = "Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075",
abstract = "Background: Antimitotic tubulin-binding BPR0L075 is structurally analogous to the vascular-disrupting combretastatin A-4. Materials and Methods: In vitrei in vivo models of endothelial cells cultures, Matrigel™ plug assay, tumor-bearing nude mice, and murine leukemia cells-inoculated mice were utilized to evaluate BPR0L075 for antiangiogenic and antitumoral activity spectra. Results: BPR0L075 concentration-dependently inhibited proliferation and migration of human umbilical vein endothelial cells (HUVECs), disrupted capillary tube formations of HUVECs and rat aorta endothelial cells, and suppressed in vivo VEGF-mediated angiogenesis in Matrigel™ plugs in mice. Besides inhibiting the colony growth of cancer cells, BPR0L075 suppressed growth of subcutaneously-xenografted human lung, colorectal, and cervical solid tumors in nude mice. Combination treatments of BPR0L075 plus cisplatin, compared to either agent alone, demonstrated a stronger growth inhibition against the tumor xenografts in nude mice and longer lifespan in the leukemia mice. Conclusion: BPR0L075 is an antitumoral and antiangiogenic agent and potentiates the anticancer activity of cisplatin.",
keywords = "Angiogenesis, Cisplatin, Combretastatin, Microtubule, Vascular disrupting agent",
author = "Chen, {Ching Ping} and Hu, {Chih Bo} and Yeh, {Kai Chia} and Song, {Jen Shin} and Yeh, {Teng Kuang} and Tung, {Fei Feng} and Hwang, {Ling Ling} and Tseng, {Huan Yi} and Huang, {Yu Chen} and Shy, {Horng Shing} and Hsieh, {Su Huei} and Shen, {Chien Chang} and Wang, {Hsin Sheng} and Hsieh, {Hsing Pang} and Liou, {Jing Ping} and Chao, {Yu Sheng} and Chen, {Chiung Tong}",
year = "2010",
month = "7",
language = "English",
volume = "30",
pages = "2813--2822",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075

AU - Chen, Ching Ping

AU - Hu, Chih Bo

AU - Yeh, Kai Chia

AU - Song, Jen Shin

AU - Yeh, Teng Kuang

AU - Tung, Fei Feng

AU - Hwang, Ling Ling

AU - Tseng, Huan Yi

AU - Huang, Yu Chen

AU - Shy, Horng Shing

AU - Hsieh, Su Huei

AU - Shen, Chien Chang

AU - Wang, Hsin Sheng

AU - Hsieh, Hsing Pang

AU - Liou, Jing Ping

AU - Chao, Yu Sheng

AU - Chen, Chiung Tong

PY - 2010/7

Y1 - 2010/7

N2 - Background: Antimitotic tubulin-binding BPR0L075 is structurally analogous to the vascular-disrupting combretastatin A-4. Materials and Methods: In vitrei in vivo models of endothelial cells cultures, Matrigel™ plug assay, tumor-bearing nude mice, and murine leukemia cells-inoculated mice were utilized to evaluate BPR0L075 for antiangiogenic and antitumoral activity spectra. Results: BPR0L075 concentration-dependently inhibited proliferation and migration of human umbilical vein endothelial cells (HUVECs), disrupted capillary tube formations of HUVECs and rat aorta endothelial cells, and suppressed in vivo VEGF-mediated angiogenesis in Matrigel™ plugs in mice. Besides inhibiting the colony growth of cancer cells, BPR0L075 suppressed growth of subcutaneously-xenografted human lung, colorectal, and cervical solid tumors in nude mice. Combination treatments of BPR0L075 plus cisplatin, compared to either agent alone, demonstrated a stronger growth inhibition against the tumor xenografts in nude mice and longer lifespan in the leukemia mice. Conclusion: BPR0L075 is an antitumoral and antiangiogenic agent and potentiates the anticancer activity of cisplatin.

AB - Background: Antimitotic tubulin-binding BPR0L075 is structurally analogous to the vascular-disrupting combretastatin A-4. Materials and Methods: In vitrei in vivo models of endothelial cells cultures, Matrigel™ plug assay, tumor-bearing nude mice, and murine leukemia cells-inoculated mice were utilized to evaluate BPR0L075 for antiangiogenic and antitumoral activity spectra. Results: BPR0L075 concentration-dependently inhibited proliferation and migration of human umbilical vein endothelial cells (HUVECs), disrupted capillary tube formations of HUVECs and rat aorta endothelial cells, and suppressed in vivo VEGF-mediated angiogenesis in Matrigel™ plugs in mice. Besides inhibiting the colony growth of cancer cells, BPR0L075 suppressed growth of subcutaneously-xenografted human lung, colorectal, and cervical solid tumors in nude mice. Combination treatments of BPR0L075 plus cisplatin, compared to either agent alone, demonstrated a stronger growth inhibition against the tumor xenografts in nude mice and longer lifespan in the leukemia mice. Conclusion: BPR0L075 is an antitumoral and antiangiogenic agent and potentiates the anticancer activity of cisplatin.

KW - Angiogenesis

KW - Cisplatin

KW - Combretastatin

KW - Microtubule

KW - Vascular disrupting agent

UR - http://www.scopus.com/inward/record.url?scp=77955799467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955799467&partnerID=8YFLogxK

M3 - Article

C2 - 20683017

AN - SCOPUS:77955799467

VL - 30

SP - 2813

EP - 2822

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -